Survodutide: Trials and FDA Status
Survodutide is a glp-1/glucagon dual agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational · phase 3
- Phase
- Phase 3
- Sponsor
- Boehringer Ingelheim
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT04667377, NCT04153929, NCT04771273, NCT06066515, NCT06066528
Reported results
- 2026SYNCHRONIZE-1 phase 3 (NEJM 2026): weight change at 76 weeks“At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group”pubmed.ncbi.nlm.nih.gov
- 2026SYNCHRONIZE-2 phase 3 (NEJM 2026): weight change at 76 weeks in type 2 diabetes“The mean weight change at week 76 according to the treatment-regimen estimand (which assessed effects regardless of whether the trial regimen was discontinued or interrupted or whether other antiobesity therapies were used) was -8.2% (95% confidence interval [CI], -9.2 to -7.2) in the 3.6-mg group, -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mg group, and -3.9% (95% CI, -4.9 to -2.9) in the placebo group”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- FDA warning letters to five research-peptide sellersEnforcement
- Published in The New England journal of medicine (2026): Survodutide Once Weekly for the Treatment of Adults with Obesity.
- Published in The New England journal of medicine (2026): Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
- Published in Nature medicine (2026): Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
- NCT06066528 (SYNCHRONIZE™-2; Phase 3): primary completion
- NCT06066515 (SYNCHRONIZE™-1; Phase 3): primary completion
- Published in The lancet. Diabetes & endocrinology (2024): Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
- Published in The New England journal of medicine (2024): A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
- NCT06066528 (SYNCHRONIZE™-2; Phase 3): study start
- NCT06066515 (SYNCHRONIZE™-1; Phase 3): study start
- NCT04771273 (A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3); Phase 2): primary completion
- NCT06066515 (SYNCHRONIZE™-1; Phase 3): first posted on ClinicalTrials.gov
- NCT06066528 (SYNCHRONIZE™-2; Phase 3): first posted on ClinicalTrials.gov
- NCT04667377 (A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight; Phase 2): primary completion
- NCT04153929 (A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.; Phase 2): primary completion
- NCT04771273 (A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3); Phase 2): study start
- NCT04667377 (A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight; Phase 2): study start
- NCT04771273 (A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3); Phase 2): first posted on ClinicalTrials.gov
- NCT04667377 (A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight; Phase 2): first posted on ClinicalTrials.gov
- NCT04153929 (A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.; Phase 2): study start
- NCT04153929 (A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.; Phase 2): first posted on ClinicalTrials.gov
What the survodutide registry entries specify
The phase 3 trial in people without diabetes (NCT06066515) is titled as a randomised, double-blind, 76-week study of BI 456906 against placebo in overweight or obesity without type 2 diabetes.[4]
It enrolled 726 participants.[4]
It is completed: it started 2023-11-25 and reached primary completion on 2025-12-02.[4]
The phase 3 trial in type 2 diabetes enrolled 755 participants.[5]
It is also completed, running from 2023-11-27 to primary completion on 2025-12-12.[5]
The phase 2 liver trial (NCT04771273) lists a planned maintenance arm at 6.0 mg.[3]
Primary endpoints and trial length
The no-diabetes trial's first primary outcome is percentage change in body weight from baseline to Week 76.[4]
Its second primary outcome is whether participants reach a body weight reduction of at least 5%.[4]
From start to primary completion, the no-diabetes trial spans 105 weeks and the diabetes trial 107 weeks.
Calculated from NCT06066515 start 2023-11-25, primary completion 2025-12-02, type ACTUAL; NCT06066528 start 2023-11-27, primary completion 2025-12-12, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days)
Published phase 3 results
In SYNCHRONIZE-1, weight change at week 76 was -12.2% at 3.6 mg and -13.0% at 6.0 mg, against -5.4% on placebo (treatment-regimen estimand).[9]
In the diabetes trial, the placebo group also lost weight (-3.9%), against -8.2% at 3.6 mg and -9.8% at 6.0 mg.[10]
Gastrointestinal symptoms occurred in 80.9% of the 3.6 mg group and 89.7% of the 6.0 mg group, against 47.9% on placebo.[9]
Common questions
Is survodutide in phase 3?
Yes. Two phase 3 trials, both with a 76-week primary endpoint, have reached primary completion.[4]
Is survodutide FDA approved?
FDA's statement lists survodutide among the drugs it says have been illegally sold as unapproved products labeled "for research purposes" or "not for human consumption".[12]
Sources
- 1A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight (NCT04667377)ClinicalTrials.gov (U.S. National Library of Medicine) · 2020clinicaltrials.govAccessed 2 Oct 2026
- 2A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. (NCT04153929)ClinicalTrials.gov (U.S. National Library of Medicine) · 2019clinicaltrials.govAccessed 2 Oct 2026
- 3A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) (NCT04771273)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 4SYNCHRONIZE™-1: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (NCT06066515)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 5SYNCHRONIZE™-2: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (NCT06066528)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 6FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 7Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
- 8A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
- 9Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
- 10Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
- 11Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
- 12Official web pageOfficial web page · web page
Found an error? Report a correction.